Continuous Glucose Monitoring (CGM) Devices Market, by Component (Transmitters, Receivers, Insulin Pumps, and Sensors) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analy

Continuous Glucose Monitoring (CGM) Devices Market, by Component (Transmitters, Receivers, Insulin Pumps, and Sensors) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Continuous Glucose Monitoring (CGM) devices provide real-time information on blood glucose levels, less invasively than conventional glucose monitoring devices, marking a remarkable change in diabetes care. Continuous glucose monitoring devices automatically tracks blood sugar levels throughout the day that can be analyzed to make more informed decisions throughout the day about how to balance your food, physical activity, and medicines. Effective approach such as continuous glucose monitoring can prevent the complications associated with diabetes as well as premature death that can result from all types of diabetes. CGM system requires less number of finger sticks and allows for data from the device to be transferred and shared for further analysis. The rise in continuous glucose monitoring market is majorly attributed to the rise in incidence of diabetes and to curb the complications associated with the disease.

Market Dynamics

The major factors driving growth of the continuous glucose monitoring (CGM) devices market include rapid technological advancements and convenience offered by the continuous glucose monitoring devices over the self-monitoring devices such as minimized finger pricks and special software for data tracking. For instance, in February 2022, Tandem Diabetes Care, Inc., medical device company based in the U.S., announced U.S. Food and Drug Administration (FDA) clearance of the t: slim X2 insulin pump with Control-IQ technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL), and the first system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. The system integrates with Dexcom G6 (product name) continuous glucose monitoring (CGM), which requires no fingersticks for calibration or diabetes treatment decisions. Control-IQ technology for the t: slim X2 insulin pump is the first automated insulin dosing software in a new interoperable automated glycemic controller category that automatically adjusts insulin delivery to a person with diabetes by connecting to an alternate controller-enabled insulin pump (ACE pump) and integrated continuous glucose monitor (iCGM). This is the third category classified by the FDA for the interoperability of devices as a complete automated insulin dosing (AID) system.

Key features of the study:

• This report provides an in-depth analysis of the global continuous glucose monitoring (CGM) devices market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global continuous glucose monitoring (CGM) devices market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Medtronic, Dexcom, Inc., Abbott Laboratories, Medtrum Technologies, Inc., Tandem Diabetes Care, Senseonics, Glycens, Insulet Corporation, and Nemaura Medical, Inc., STMicroelectronics, NXP Semiconductors, Qualcomm, Taiwan Semiconductor Manufacturing Company Limited, GE Healthcare, Microchip Technology Inc., Texas Instruments Inc. and Micron Technology Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global continuous glucose monitoring (CGM) devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global continuous glucose monitoring (CGM) devices market

Detailed Segmentation:

• Global Continuous Glucose Monitoring (CGM) Devices Market, By Component:
• Transmitters
• Receivers
• Insulin Pumps
• Sensors
• Global Continuous Glucose Monitoring (CGM) Devices Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Medtronic *
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Dexcom, Inc.
• Abbott Laboratories
• Medtrum Technologies, Inc.
• Tandem Diabetes Care
• Senseonics
• Glycens
• Insulet Corporation
• Nemaura Medical, Inc.
• STMicroelectronics
• NXP Semiconductors
• Qualcomm
• Taiwan Semiconductor Manufacturing Company Limited
• GE Healthcare
• Microchip Technology Inc.
• Texas Instruments Inc.
• Micron Technology Inc.

“*” marked represents similar segmentation in other categories in the respective section.